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Objectives. This study sought to compare, head to head, the two 
most popular pharmacologic stress echocardiographic tests-- 
dipyridamole and dobutamine--with state of the art protocols in 
a large multicenter prospective study. 
Background. In the continuing quest for ideal diagnostic accu- 
racy, pharmacologic stress echocardiography has quickly moved 
over the years from low to high dose regimens and is currently 
performed with atropine coadministration. 
Methods. Dobutamine (up to 40/tg/kg body weight per min) 
plus atropine (up to 1 mg over 4 h) and dipyridamole (up to 
0.84 mg/kg per min over 10 h) plus atropine (up to 1 mg over 4 h) 
stress echocardiography was performed on different days, in 
random order and within 1 week in 360 patients with chest pain 
syndrome. Thirteen different echocardiographic laboratories, all 
fulfilling quality control criteria for stress echocardiographic 
reading, contributed to the study. 
Results. No major complications occurred uring either test. 
The test was interrupted before achievement of predetermined nd 
points for limiting side effects in 37 dobutamine-atropine a d 7 
dipyridamole-atropine str ss echocardiographic studies (feasibil- 
ity 90% vs. 98%, p < 0.01). Diagnostic accuracy was assessed ina 
subset of 110 patients with no obvious rest dyssynergy (akinesia or 
dyskinesia) who underwent coronary angiography independently 
of test results and within 1 week of testing. Significant coronary 
artery disease (>5(F/c diameter reduction in at least one major 
coronary vessel by quantitative coronary angiography) was found 
in 92 patients. Sensitivity for detection of coronary artery disease 
was 84% (77 of 92) for dobutamine-atropine a d 82% (75 of 92) 
for dipyridamole-atropine stress echocardiography (p = NS), 
with a specificity of 89% (16 of 18) for dobutamine-atropine a d 
94% (17 of 18) for dipyridamole-atropine str ss echocardiography 
(p = NS). A significant correlation was present between peak 
wall motion score index during dipyridamole-atropine and 
dobutamine-atropine stress echocardiography (r = 0.83, p < 
0.0001). 
Conclusions. Dobutamine-atropine a d dipyridamole-atropine 
stress echocardiography aresafe and feasible, although submaxi- 
mal studies are more frequent with dobutamine. The two stresses 
have comparable accuracy in the detection of angiographically 
assessed coronary artery disease, although dobutamine is mar- 
ginally more sensitive and dipyridamole marginally more specific. 
Stratification ofthe ischemic response inthe space domain is also 
comparable with the two stresses. 
(J Am Coil Cardiol 1996;27:1164-70) 
Pharmacologic stress echocardiography is now considered an 
established, cost-effective alternative to myocardial scintigra- 
play (1-4). The two most popular pharmacologic stresses used 
in conjunction with two-dimensional echocardiography are 
dipyridamole (5) and dobutamine (6). The two drugs have 
From the Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche 
(CNR), Pisa, Italy. This study was supported in part by a grant from the CNR, 
Pisa, Italy. A complete list of participating institutions and investigators for the 
EPIC and EDIC study groups appears in references 16 and 17, respectively. 
Manuscript received November 10, 1994; revised manuscript received Au- 
gust 11, 1995, accepted November 22, 1995. 
Address for correspondence: Dr. Alessandro Pingitore, CNR, Institute of 
Clinical Physiology, Via Paolo Savi, 8, 56100 Pisa, Italy. 
completely different biochemical ctions: Dipyridamole inhib- 
its cellular uptake of endogenous adenosine (5), whereas 
dobutamine is an agonist of beta- and alpha-adrenoreceptors 
(6). Accordingly, they act through different coronary hemody- 
namic mechanisms: Dipyridamole provokes a reduction of 
absolute subendocardial perfusion through flow rnaldistribu- 
tion phenomena induced by inappropriate arteriolar vasodila- 
tion, whereas dobutamine increases myocardial oxygen de- 
mand. Despite the different underlying biochemical and 
coronary hemodynamic mechanisms, both drugs tend to in- 
duce ischemia in the same myocardial territory, fed by a 
critically stenosed artery, apparently with a similar accuracy for 
the detection of angiographically assessed coronary artery 
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disease (7-13), although dobutamine probably has slightly 
greater sensitivity in patients with single-vessel disease (9,12). 
However, the field of stress echocardiography is in rapid 
evolution. In the continuing quest for ideal diagnostic accu- 
racy, pharmacologic stresses have experienced a sort of parallel 
life, quickly moving over the years from low to high dose 
regimens and eventually to atropine coadministration, which 
increases myocardial oxygen demand, mainly through addi- 
tional chronotropic stress. Although both dipyridamole (14) 
and dobutamine (15) have been individually shown to increase 
their diagnostic accuracy by atropine coadministration, a direct 
comparison of the atropine protocols of the two tests is not yet 
available. The aim of the present study was to compare, head 
to head, the two most popular pharmacologic stress echocar- 
diographic tests with state of the art protocols consisting of 
aggressive dosing and atropine supplementation a large- 
scale multicenter basis. For this purpose, two sets of data are 
presented: the first relating to 360 patients comparing the 
feasibility, safety and side effects of dipyridamole-atropine 
versus dobutamine-atropine stress echocardiography; and the 
second set relating to 110 patients without obvious rest re- 
gional dyssynergy (akinesia or dyskinesia) who underwent 
coronary angiography in three different centers independently 
of test results and within 1 week of testing. These data are used 
to determine the diagnostic accuracy of the two tests for 
detecting coronary artery disease. Patients were enrolled by 
13 laboratories with experience and expertise in performing 
and interpreting both pharmacologic stress echocardiographic 
modalities. The stress echocardiographic reading was per- 
formed in each center by a cardiologist who had passed the 
quality control procedures of stress echoeardiographic reading 
and had entered the network of the Echo Persantine Interna- 
tional Cooperative (EPIC) (16) and Echo Dobutamine Inter- 
national Cooperative (EDIC) (17) studies. 
Methods 
Study patients. Between January 1993 and January 1994, 
360 in-hospital or outpatients (300 men, 60 women; mean 
[_+SD] age 60 _+ 9 years) referred to the echocardiography 
laboratory for evaluation of chest pain syndrome or risk 
stratification in patients with known coronary artery disease, 
or both, were enrolled in the study. Exclusion criteria were 
congestive heart failure, unstable angina, severe congenital or 
valvular heart disease or documented cardiomyopathy. Pa- 
tients with severe hypertension (systolic pressure ->200 mm Hg 
and diastolic pressure ->120 mm Hg), recent malignant ven- 
tricular arrhythmias and severe asthmatic or chronic obstruc- 
tive pulmonary disease (with dependence on chronic phylline 
therapy or wheezing on physical examination, or both) were 
also excluded because these conditions represent a relative 
contraindication to either dobutamine or dipyridamole stress 
testing (5,6). Informed consent o undergo two stress tests 
was obtained from all patients. Each patient performed ipyr- 
idamole and dobutamine stress testing in random sequence 
within a 5-day period. Three hundred four patients were 
withdrawn from therapy at the time of testing; 56 underwent 
testing under identical antianginal therapy, which consisted of 
nitrates in 16, calcium antagonists in 15, beta-adrenergic 
blocking agents in 12 and combined therapy (nitrates and 
calcium antagonists or nitrates and beta-blockers) in 13. That 
the overwhelming majority of patients received no therapy at 
the time of testing does not imply that this was a low risk 
cohort; rather, it reflects the prevailing cardiologic policy in 
many non-U.S, countries that when clarifying a diagnosis of 
ischemic heart disease is of prime importance, it is recom- 
mended to stop all anti-ischemic treatment before testing (17). 
The relative diagnostic accuracy of the two tests was 
assessed in a subset of 110 patients with no obvious rest 
regional dyssynergy (akinesia or dyskinesia) who underwent 
quantitative coronary angiography independently of test re- 
sults and within 1 week of testing. Of these 110 patients, 17 had 
had a previous (>3 months) myocardial infarction; 13 had a 
recent (<10 days) uncomplicated myocardial infarction; 62 
had angina pectoris; and 18 complained of atypical chest pain. 
Ninety-one patients were withdrawn from antianginal therapy 
at the time of testing; 19 underwent testing under identical 
antianginal therapy, which consisted of nitrates in 4, calcium 
antagonists in 5, beta-blockers in 2 and combined therapy 
(nitrates and calcium antagonists or nitrates and beta- 
blockers) in 8. The decision to submit he patient o coronary 
angiography was made by the referring physician, according to 
individual patient needs. Stress echocardiographic results were 
available to the referring physician, but stress echocardio- 
graphic positivity was not in and of itself an indication for 
coronary angiography. 
Angiograms and stress echocardiographic data were inde- 
pendently assessed by observers unaware of the results of the 
other test. 
Stress protocols. Dipyridamole-atropine. According to the 
protocol originally proposed by Picano et al. (14), dipyridamole 
was infused intravenously ata dose of 0.56 mg/kg body weight 
over 4 min, followed by 4 min of no dose and then, if the test 
was still negative, 0.28 mg/kg over 2 min. The cumulative dose 
was therefore 0.84 mg/kg over 10 min. When no end point was 
reached at 3 min after the end of dipyridamole infusion, 
atropine (in four divided doses of 0.25 mg up to a maximum of 
1 rag) was given (14). 
Dobutarnine-atropine. According to the protocol originally 
proposed by McNeill et al. (15) and adopted in the EDIC study 
(17), dobutamine was infused in 3-min dose increments, tart- 
ing from 5 /zg/kg per min and increased to 10, 20, 30 and 
40/zg/kg per min. When no end point was reached, atropine 
(in four divided doses of 0.25 mg up to a maximum of I rag) 
was added to the continuing 40 /zg/kg per min dobutamine 
infusion. 
Interruption criteria for pharmacologic stress tests. The 
diagnostic end points of the test were 1) development of 
obvious echocardiographic positivity (new or worsening dys- 
synergy); 2) peak atropine dose; 3) 85% of target heart rate; 
and 4) achievement of conventional (severe chest pain or ST 
segment shift >2.5 mV, or both) nonechocardiographic "is h- 
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Table 1. Hemodynamic Findings in 360 Patients (mean - SD) 
Rest DIPASE DOBASE 
p Value 
Rest vs. DIPASE Rest vs. DOBASE DIPASE vs. DOBASE 
Heart rate (beats/min) 68 _+ 14 97 _+ 14 117 _+ 21 0.0001 
Diastolic blood pressure (mm Hg) 75 _+ 7 79 +_ 6 81 _+ 8 0.6 
Systolic blood pressure (mm Hg) 132 _+ 18 138 _+ 19 156 _+ 25 0.6 
Rate-pressure product (beats/rain 9,085 _+ 2,240 13,303 +2,592 18,289 _+ 4,594 0.0001 
× mm Hg) 
0.0001 0.0001 
0.5 0.5 
0.001 0.001 
0.0001 0.0001 
DIPASE = dipyridamole-atropine stress echocardiography; DOBASE = dobutamine-atropine str ss echocardiography. 
emic" end points. The test was also stopped in the absence of 
diagnostic end points for one of the following reasons of 
submaximal nondiagnostic tests: 1) intolerable symptoms or 2) 
limiting asymptomatic side effects, consisting of a) hyperten- 
sion (systolic blood pressure >220 mm Hg, diastolic blood 
pressure >120 mm Hg); b) hypotension (relative or absolute) 
(>30 mm Hg decrease in blood pressure); c) supraventricular 
arrhythmias, supraventricular tachycardia or atrial fibrillation; 
or d) ventricular arrhythmias, ventricular tachycardia or fre- 
quent and polymorphous premature ventricular beats. 
Echocardiographic analysis. Two-dimensional echocardio- 
graphic monitoring was performed throughout and up to 5 rain 
after the stop of the drug infusion. Two-dimensional images 
were recorded at baseline and at the end of each step. 
For each patient, left ventricular function was evaluated at 
baseline and at peak stress with semiquantitative assessment of 
a wall motion score index, calculated with the 16-segment 
model of the left ventricle, each segment ranging from 1 = 
normal/hyperkinetic o 4 = dyskinetic, according to the rec- 
ommendations of the American Society of Echocardiography 
(19). A test result was considered positive when the wall motion 
score increased by one grade or more at peak stress (for 
example, a normal segment becoming hypokinetic, akinetic 
or dyskinetic; or a hypokinetic segment becoming akinetic or 
dyskinetic); however, an akinesia becoming dyskinesia was not 
considered a criterion of positivity, because this can result from 
passive stretching phenomena r ther than from "active" isch- 
emia (16). Inadequately visualized segments were not scored. 
In tests giving positive results, the ischemia-free stress time, 
that is, the time in minutes from the beginning of drug infusion 
to the development of stress-induced dyssynergy, was also 
evaluated. 
At each center, one observer who had passed the quality 
control procedures detailed elsewhere (16) reviewed the study; 
his or her reading was entered irectly into the data bank. 
Angiographic data, Patients underwent selective right and 
left coronary arteriography using either the Judkins or the 
Sones technique. Angiographic studies were performed and 
interpreted by experienced observers who ignored the results 
of stress echocardiography. Cine films of patients entering the 
sensitivity and specificity analysis were read in Pisa, Italy, with 
an angiographic projection system (CAP/35 B II) allowing 
frame by frame analysis, selection and magnification of the 
segments of interest. All stenotic segments were evaluated by 
an automatic edge detection system (Mipron, Kontron). Mag- 
nification of the region of interest during assessment was 
possible. A region of interest of 512 × 512 pixels was manually 
selected and digitized by using a high quality VIDICON 
videocamera. The lumen edges were detected on the basis of 
the weighted sum of the first- and second-derivative functions 
of the brightness profile of each scan line perpendicular to the 
vessel centerline. The percent diameter stenosis was measured 
in the projection in which the stenosis appeared to be most 
severe. A vessel was considered to have significant obstruction 
if its diameter was narrowed ->50%. The previously assessed 
intraobserver and interobserver variabilities of the method in 
our laboratory were 7% and 6%, respectively (20). 
Data collection. Pertinent medical history, demographic 
features and echocardiographic f ndings were assessed and 
coded on computer forms for all patients at the time of the 
study. Complete data sets were obtained for all patients and 
entered into a data base for analysis. 
Statistical analysis. Data are expressed as mean value _+ 
SD. Continuous variables were analyzed according to the 
Student t test. Dichotomous variables we~c compared by 
chi-square analysis. Linear regression analysis was performed. 
Calculations of sensitivity, specificity and accuracy were done 
according to standard efinitions. A p value <0.05 was consid- 
ered significant. 
Results  
Hemodynamic variables. Heart rate, systolic and diastolic 
blood pressure and rate-pressure product both at baseline and 
at peak stress are presented in Table 1. The increase in heart 
rate and rate-pressure product was significantly higher with 
dobutamine-atropine than dipyridamole-atropine stress echo- 
cardiography. 
Stress tolerability. No major complications occurred ur- 
ing either stress test. Minor but limiting side effects occurred in 
37 dobutamine-atropine and 7 dipyridamole-atropine stress 
echocardiographic studies, yielding an overall feasibility of 
90% and 98%, respectively (p < 0.01). Limiting side effects 
were more often asymptomatic during dobutamine-atropine 
stress; in order of frequency, they consisted of ventricular 
tachyarrhythmias in 19 patients, nausea and headache in 7, 
hypertension i  4, atrial tachyarrhythmias n 4 and hypotension 
in 3. Limiting side effects were more often symptomatic during 
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dipyridamole-atropine stress; in order of frequency, they con- 
sisted of headache in4 patients and nausea with bradycardia or 
hypotension i 3. The feasibility of dobutamine-atropine stress 
echocardiography was 96% at a dose of -<20/zg/kg per min; 
93% at a dose -<30 p~g/kg per min and 91% at a dose of 
40 /zg/kg per min. The feasibility of dipyridamole-atropine 
stress echocardiography was 99% at a dose of 0.56 mg/kg and 
98% at a dose of 0.84 mg/kg. 
Stress echoeardiographic findings. Dipyridamole-atropine 
stress echocardiographic positivity occurred in 145 patients 
and dobutamine-atropine stress echocardiographic positivity 
in 176. Overall agreement between the two tests regarding 
positivity or negativity was 82%. In particular, 125 patients had 
a positive response to both tests; 163 patients had a negative 
response to both tests; 20 patients had a negative response to 
dobutamine-atropine and a positive response to dipyrida- 
mole-atropine stress echocardiography; and 51 had a negative 
response to dipyridamole-atropine and a positive response to 
dobutamine-atropine stress echocardiography. 
Angiographic data. Of the 110 study patients ubmitted to 
coronary angiography within 1 week of testing and with no 
obvious rest dyssynergy (akinesia or dyskinesia), 18 showed 
normal and 92 diseased coronary arteries. Of the latter group, 
41 had single-, 32 double-, 18 triple- and 1 left main vessel 
disease. 
Correlation between angiographic data and stress results. 
Sensitivity of dipyridamole-atropine and dobutamine-atropine 
stress echocardiography forangiographically assessed coronary 
artery disease was 82% and 84%, respectively (p < 0.6). For 
both tests, the sensitivity increased significantly from lower 
doses (0.56 mg/kg over 4 min for dipyridamole; 20 p,g/kg per 
min for dobutamine) to higher doses (0.84 mg/kg for dipyri- 
damole; 40 txg/kg per min for dobutamine) and increased 
further after atropine coadministration (Fig. 1A). Atropine 
caused asignificant increase in the sensitivity of dipyridamole- 
atropine stress echocardiography (82% vs. 68% for dipyri- 
damole alone, p < 0.05) but not dobutamine-atropine stress 
• echocardiography (84% vs. 78% for dobutamine alone, p < 
0.3). In patients with coronary artery disease, echocardio- 
graphic positivity after atropine administration occurred in 12 
patients with dipyridamole (7 with single-, 5 with multivessel 
disease) and 5 with dobutamine (1 with single-, 2 with multi- 
vessel disease). Of the 17 patients with false negative 
dipyridamole-atropine results, none had a submaximal test; of 
the 15 patients with false negative dobutamine-atropine re- 
sults, 6 (3 with multivessel, 3 with single-vessel disease) had 
submaximal test results. Of the three patients with single-vessel 
disease, two had ->90% stenosis. 
Specificity of dipyridamole-atropine and dobutamine- 
atropine stress echocardiography was 94% and 89%, respec- 
tively (p < 0.5) (Fig. 1B). The overall diagnostic accuracy was 
84% for both tests. There was a linear correlation between 
peak wall motion score index values of the two stresses (r = 
0.83, p < 0.01) (Fig. 2). As shown in Table 2, low dose 
positivity occurred more frequently in patients with multivessel 
disease for both dobutamine-atropine and dipyridamole- 
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Figure 1. A, Bar graph showing sensitivity of dipyridamole-atropine 
and dobutamine-atropine str ss echocardiography for 92 patients with 
angiographically assessed coronary artery disease. For each test, the 
sensitivity achieved with low dose regimens (0.56 mg/kg and 20 ~g/kg 
per min for dipyridamole-atropine a ddobutamine-atropine str ss 
echocardiography, respectively), high dose regimens (0.84 mg/kg and 
40/~g/kg per min for dipyridamole-atropine a d dobutamine-atropine 
stress echocardiography, respectively) and atropine coadministration 
(up to 1 mg for both dipyridarnole-atropine and dobutamine-atropine) is 
shown. B, Bar graph showing the similar specificity of dipyridamole- 
atropine and dobutamine-atropine str ss echocardiography for angio- 
graphically assessed coronary artery disease. Eighteen patients had no 
coronary artery disease. Open areas = atropine positivity; hatched 
areas = high dose positivity; solid areas = low dose positivity. 
atropine stress echocardiography. Of the 32 patients with low 
dose positivity on dobutamine-atropine stress echocardiogra- 
phy, 15 also had a positive response to dipyridamole-atropine 
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Figure 2. Scatter plots showing a significant linear correlation between 
extent and severity of ischemia, expressed as the peak wall motion 
score index (WMSI), during dipyridamole-atropine str ss echocardi- 
ography and peak wall motion score index during dobutamine- 
atropine stress echocardiography in 110 patients, r = 0.83; p < 0.001. 
stress echocardiography, and of 45 patients with high dose 
positivity on dobutamine-atropine stress echocardiography, 24 
also had a positive response to high dose dipyridamole- 
atropine stress echocardiography. Peak wall motion score 
index values were similar in patients with one-, two- and 
three-vessel disease for both dipyridamole-atropine (1.36 _+ 
0.3, 1.44 z 0.27 and 1.54 _+ 0.38, respectively, p < 0.1) and 
dobutamine-atropine stress echocardiography (1.37 _+ 0.35, 
1.4 _+ 0.33 and 1.44 _+ 0.36, respectively, p < 0.7). 
As shown in Table 2, 76% of patients with single-vessel 
disease had a positive response to low or high dose dobut- 
amine, whereas only 54% had a positive response to dipyri- 
damole echocardiography before the addition of atropine. 
After atropine, dobutamine and dipyridamole stress ensitivity 
rose to 78% and 71%, respectively. 
Table 2. Distribution of Test Positivity in Relation to Extent of 
Coronary Artery Disease 
Coronary Artery Disease 
0 Vessel 1 Vessel 2 Vessel 3 Vessel 
(n - 18) (n : 41) (n : 32) (n : 19) 
DOBASE positivity 
Total 2 (11%) 32 (78%) 28 (87%) 17 (89% 
Low dose 1 (5.5%) 10 (24%) 14 (44%) 8 (42% 
High dose 1 (5.5%) 21 (52%) 11 (34%) 8 (42% 
Atropine 0 (0%) 1 (2%) 3 (9%) 1 (5% 
DOBASE negativity 16 (89%) 9 (22%) 4 (13%) 2 (11% 
DIPASE positivity 
Total 1 (5.5%) 29 (71%) 29 (91%) 2 (89% 
Low dose 0 (0%) 12 (29%) 12 (38%) 7 (37% 
High dose 1 (5.5%) 10 (25%) 14 (44%) 8 (42% 
Atropine 0 (0%) 7 (17%) 3 (9%) 2 (10% 
DIPASE negativity 17 (94.5%) 12 (29%) 3 (9%) 2 (11% 
Data presented are number (%) of patients. Abbreviations as in Table 1. 
Discuss ion  
The results of this prospective, large-scale, multicenter 
study show that both dobutamine-atropine and dipyridamole- 
atropine stress echocardiography are feasible and safe, al- 
though submaximal studies occur more frequently with dobut- 
amine. The two stresses have comparable accuracy for the 
detection of angiographically assessed coronary artery disease, 
although dobutamine is marginally more sensitive and dipyr- 
idamole marginally more specific. Atropine coadministration is 
useful with both drugs to achieve the optima ! diagnostic 
accuracy of pharmacologic stress echocardiography, although 
the atropine step-up in sensitivity is more substantial with 
dipyridamo!e-atropine stress, at least in our cohort, which 
was largely withdrawn from beta-blockers. This class of 
antianginal drugs is known to reduce markedly the sensitiv- 
ity of dipyridamole (21,22) and dobutamine stress (23) but 
not that of dobutamine-atropine stress echocardiography 
(23). 
Mechanisms of ischemia during pharmacologic stress. 
Tests exploring coronary stenosis can induce ischemia in the 
presence of a critical reduction in coronary flow reserve 
through two basic mechanisms: 1) an increase in oxygen 
demand, exceeding the fixed supply; and 2) flow maldistribu- 
tion, due to inappropriate coronary vasodilation (4). Dobut- 
amine is an ischemic stressor that acts mainly by increasing 
myocardial oxygen demand through myocardial adrenorecep- 
tor stimulation (6,24). This substantial rise in determinants of
myocardial oxygen consumption may provoke a supply- 
demand mismatch in the presence of a fixed reduction in 
coronary flow reserve. Dipyridamole acts in a different way. 
Although there is a modest rise in the determinants of oxygen 
consumption, mainly through chronotropic stress magnified by 
atropine coadministration, the major mechanism is certainly 
flow maldistribution, with "vertical" and "horizontal" steal 
phenomena ultimately determining a fall in absolute subendo- 
cardial flow (5,24). The "paradox" of a regional dyssynergy 
that may occur with an increase in transmural f ow can be 
easily understood by considering that regional function is 
closely related to subendocardial flow much more than to the 
transmural or subepicardial flow (25). 
Comparison with previous studies. The results of the 
present study can be considered consistent with the available 
experimental (26-28) and clinical (7-12) evidence. In animal 
experiments, a higher frequency of transient dyssynergy with 
dobutamine than with dipyridamole (100% vs. 56%) was 
reported by Fung et al. (26) in a dog model. However, 
submaximal doses of both dipyridamole (0.56 mg/kg) and 
dobutamine (15 tzg/kg per rain) were used in that study (26). In 
another recent experimental study, high dose dobutamine 
(40 ~g/kg) showed a higher sensitivity than high dose dipyri- 
damole (0.84 mg/kg) in the detection of single-vessel disease 
in a swine model (28). However, the two tests were not 
administered in a randomized manner, with high doses of 
dipyridamole always given before dobutamine. In this way, the 
dobutamine ischemic potential was obviously enhanced by 
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dipyridamole premedication because of the long half-life of 
high doses of dipyridamole (5). In a study by Paulsen et al. (27) 
in a dog model, in which appropriately high doses of dobut- 
amine (40 tzg/kg per min) and dipyridamole (0.7 mg/kg) were 
used, a similar effect on regional left ventricular function was 
observed. 
In the clinical setting, there are six published reports on the 
direct comparison between the two pharmacologic stresses 
encompassing a total of 402 patients, all describing a similar 
diagnostic accuracy (7-13). The results together show a similar 
overall accuracy (dipyridamole 73% vs. dobutamine 78%, p = 
NS). Dobutamine shows a higher sensitivity (76% vs. 66%), 
which is more pronounced in patients with single-vessel disease 
(75% vs. 62%), whereas no significant difference in sensitivity 
can be detected in multivessel disease (82% vs. 77%). Dipyr- 
idamole shows a significantly higher specificity (90% vs. 81%). 
This trend, derived from the analysis of published reports, is 
fully confirmed by our study, which has, however, important 
peculiarities: atropine coadministration was used with aggres- 
sive drug dosing to achieve optimal diagnostic accuracy; a 
multicenter experience was collected; a large sample was 
evaluated. 
It has been shown that dobutamine is more sensitive than 
dipyridamole in patients with single-vessel disease. In our study 
cohort, 76% of patients with single-vessel disease had a 
positive response to low or high dose dobutamine without he 
addition of atropine, whereas only 54% had a positive response 
to dipyridamole echocardiography before the addition of atro- 
pine. The atropine-induced step-up in sensitivity in patients 
with single-vessel disease was 2% with dobutamine and 17% 
with dipyridamole. This suggests that the sensitivity for detec- 
tion of single-vessel coronary disease is only marginally im- 
proved by atropine in patients undergoing dobutamine echo- 
cardiography. Atropine appears to have a significantly larger 
effect on the test positivity of dipyridamole echocardiography. 
The results of our study are also consistent with previous 
experience r porting excellent overall safety and feasibility of 
the two tests (17,29-34)with same accuracy as perfusion 
imaging (32), although limiting side effects occurred more 
frequently with dobutamine (13). The reasons for the interrup- 
tion of a submaximal test are more frequently symptomatic 
and subjective for dipyridamole (headache, nausea) and 
asymptomatic and objective for dobutamine (arrhythmias, 
hypertension, hypotension ). In other words, in submaximal 
dipyridamole-atropine str ss echocardiography, theinterrup- 
tion is more often requested by the patient, whereas it is more 
often decided by the physician with dobutamine-atropine 
stress. Arrhythmic phenomena may occur with both drugs but 
are qualitatively and quantitatively different: with dobutamine, 
complex arrhythmic phenomena are more frequent and mostly 
tachyarrhythmias (17,31,32) (paroxysmal supraventricular 
tachycardia and atrial fibrillation) but also include ventricular 
tachycardh up to ventricular fibrillation (17,31,33). With di- 
pyridamole, arrhythmic phenomena re less frequent and 
mostly represented bybradyarrhythmias (29) (bradycardia and 
atrioventricular blocks up to cardiac asystole) (29,34). 
Stratification of a positive response. An exercise stress test 
provides not only a binary (yes or no) response, but also 
stratification of a positive response (on the basis of work load, 
peak rate-pressure product, extent and severity of induced 
electrocardiographic changes) that allows grading of the un- 
derlying coronary artery disease severity. Pharmacologic stress 
echocardiography can also provide this grading of the ischemic 
response on the basis of ischemia coordinates in the space and 
time domain (5,24). The extent and severity of the induced 
dyssynergy are strong prognostic predictors with both dipyri- 
damole (16,35) and dobutamine (36). In our study, the peak 
wall motion score index values during dipyridamole and do- 
butamine were tightly correlated, in keeping with the data 
reported by Beleslin et al. (11). 
The stress echocardiographic response can also be stratified 
in the time domain. A "time to ischemia" has been used as an 
index of disease severity within each of the dipyridamole 
(20,37) and dobutamine (38,39) regimens. However, we found 
that only 47% of patients with low dose (-<20/xg/kg per min) 
dobutamine-atropine str ss echocardiographic positivity also 
frequently had a low dose (0.56 mg/kg) dipyridamole-atropine 
stress echocardiographic positivity. Conversely, only 53% of 
the patients with high dose (->30 ~g/kg per min) dobutamine- 
atropine stress echocardiographic positivity had a high dose 
(0.84 mg/kg) dipyridamole-atropine str ss echocardiographic 
positivity. This finding is not entirely surprising because the 
two protocols utilize completely different infusion rates, with 
medications with different half-lives, absorption and elimina- 
tion, which produce ischemia by completely separate means. 
Dipyridamole-atropine a d dobutamine-atropine str ss echo- 
cardiography show a comparable diagnostic accuracy and tend 
to stratify the ischemic response in a similar manner in the 
space domain, but the "time to ischemia" may differ substan- 
tially with the two stressors. 
Clinical implications. Dipyridamole and dobutamine are 
good options for the diagnosis of coronary artery disease, with 
dipyridamole having slightly better feasibility. In patients with- 
drawn from beta-blockers, atropine coadministration is espe- 
cially useful with dipyridamole, sharply increasing the subop- 
timal sensitivity of the conventional high dose test in patients 
with single-vessel disease. From the technical viewpoint, phar- 
macologic stresses allow the minimization of factors that make 
the ultrasound examination technically exacting during exer- 
cise, which induces hyperventilation a d excessive chest wall 
movement. The choice of the test depends on patient charac- 
teristics, clinical issue, local drug cost (dobutamine is less 
expensive than dipyridamole in the United States and more 
expensive in most other countries) and physician preference 
(40). It is important that all stress echocardiography laborato- 
ries become familiar with both stressors for a flexible and 
versatile diagnostic approach that may allow tailoring the best 
stress to individual patient needs. Dipyridamole and dobut- 
amine should not be viewed as competitors; rather, they are 
allies of the cardiologist, aiding in the challenging task of a 
better diagnosis of coronary artery disease. 
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